Literature DB >> 27904995

[Tocilizumab in giant cell arteritis].

J Pflugfelder1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27904995     DOI： 10.1007/s00393-016-0243-7

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


× No keyword cloud information.
  7 in total

1.  EULAR recommendations for the management of large vessel vasculitis.

Authors:  C Mukhtyar; L Guillevin; M C Cid; B Dasgupta; K de Groot; W Gross; T Hauser; B Hellmich; D Jayne; C G M Kallenberg; P A Merkel; H Raspe; C Salvarani; D G I Scott; C Stegeman; R Watts; K Westman; J Witter; H Yazici; R Luqmani
Journal:  Ann Rheum Dis       Date:  2008-04-15       Impact factor: 19.103

Review 2.  Giant cell arteritis: Current treatment and management.

Authors:  Cristina Ponte; Ana Filipa Rodrigues; Lorraine O'Neill; Raashid Ahmed Luqmani
Journal:  World J Clin Cases       Date:  2015-06-16       Impact factor: 1.337

3.  Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.

Authors:  Peter M Villiger; Sabine Adler; Stefan Kuchen; Felix Wermelinger; Diana Dan; Veronika Fiege; Lukas Bütikofer; Michael Seitz; Stephan Reichenbach
Journal:  Lancet       Date:  2016-03-04       Impact factor: 79.321

4.  Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis.

Authors:  Alfred D Mahr; Juan A Jover; Robert F Spiera; César Hernández-García; Benjamin Fernández-Gutiérrez; Michael P Lavalley; Peter A Merkel
Journal:  Arthritis Rheum       Date:  2007-08

Review 5.  Immune mechanisms in medium and large-vessel vasculitis.

Authors:  Cornelia M Weyand; Jörg J Goronzy
Journal:  Nat Rev Rheumatol       Date:  2013-11-05       Impact factor: 20.543

6.  Design of the tocilizumab in giant cell arteritis trial.

Authors:  Sebastian H Unizony; Bhaskar Dasgupta; Elena Fisheleva; Lucy Rowell; Georg Schett; Robert Spiera; Jochen Zwerina; Olivier Harari; John H Stone
Journal:  Int J Rheumatol       Date:  2013-04-07

7.  Tocilizumab induced acquired factor XIII deficiency in patients with rheumatoid arthritis.

Authors:  Sho Mokuda; Yosuke Murata; Naoya Sawada; Kenichiro Matoba; Akihiro Yamada; Makoto Onishi; Yasuaki Okuda; Kazuo Jouyama; Eiji Sugiyama; Kiyoshi Takasugi
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.